Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as GBX 6.60 ($0.08) and last traded at GBX 6.30 ($0.08), with a volume of 370347 shares trading hands. The stock had previously closed at GBX 6.40 ($0.08).
Allergy Therapeutics Stock Performance
The company has a market capitalization of £300.51 million, a P/E ratio of -105.00, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The business’s fifty day simple moving average is GBX 5.37 and its 200-day simple moving average is GBX 5.03.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- What is the Australian Securities Exchange (ASX)
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Breakout Stocks: What They Are and How to Identify Them
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
